SCHEMBL19873870

SCHEMBL19873870

O=C(O)CCCn1c(=O)c(Br)cn(C(c2ccccc2)c2ccccc2)c1=O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 1/20 0.43
▸ FABP4 P15090 3/20 0.43
▸ FABP5 Q01469 2/20 0.43
▸ KDM4E B2RXH2 1/20 0.41
▸ MAPK1 P28482 1/20 0.41
▸ HSD17B10 Q99714 1/20 0.41
▸ KAT2A Q92830 1/20 0.40
▸ KAT2B Q92831 1/20 0.40
▸ PTGER4 P35408 2/20 0.38
▸ MAPT P10636 2/20 0.38
▸ CTSG P08311 1/20 0.35
▸ CMA1 P23946 1/20 0.35
▸ TBXAS1 P24557 1/20 0.34
▸ PTGER2 P43116 1/20 0.34
▸ RXFP1 Q9HBX9 1/20 0.34
▸ HDAC3 O15379 1/20 0.34
▸ HDAC4 P56524 1/20 0.34
▸ HDAC1 Q13547 1/20 0.34
▸ HDAC7 Q8WUI4 1/20 0.34
▸ HDAC2 Q92769 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21900227 0.92 MAPT (0.46) GAAFABP4FABP5KDM4EMAPT
SCHEMBL17870725 0.84 GAA (0.47) GAAKDM4E
SCHEMBL19873831 0.78 GAA (0.43) GAAMAPK1MAPT
SCHEMBL19873721 0.76 GNRHR (0.47) FABP4FABP5KDM4EMAPK1HSD17B10
SCHEMBL21900257 0.70 GAA (0.46) GAAKDM4EMAPK1MAPTRXFP1
SCHEMBL17870751 0.69 GNRHR (0.44) MAPT
SCHEMBL11123285 0.64 PTGIR (0.54) FABP4FABP5TBXAS1
SCHEMBL8114438 0.64 PTGIR (0.54) FABP4FABP5TBXAS1
SCHEMBL411981 0.64 APEX1 (0.54) FABP4FABP5KDM4EMAPK1HSD17B10
SCHEMBL11712403 0.64 FABP4 (0.54) FABP4FABP5KDM4EMAPK1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10246422-B2 Heterocyclic compounds and use thereof in medicine and in cosmetics GALDERMA RESEARCH & DEVELOPMENT (FR) 2019-04-02 — — US disclosed
US-20180050992-A1 NOVEL HETEROCYCLIC COMPOUNDS AND USE THEREOF IN MEDICINE AND IN COSMETICS GALDERMA RESEARCH & DEVELOPMENT (FR) 2018-02-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180050992-A1 NOVEL HETEROCYCLIC COMPOUNDS AND USE THEREOF IN MEDICINE AND IN COSMETICS MC1R, CALCRL, BDKRB2 GAA 1335/4885FABP4 2201/4885FABP5 2857/4885
US-10246422-B2 Heterocyclic compounds and use thereof in medicine and in cosmetics MC1R, BDKRB2, CCKBR GAA 1096/4885FABP4 2283/4885FABP5 3093/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback